WeVote
Log In

Bill

Bill

HB 2769

MEDICAL LICENSE REVIEW

104th Regular Session Introduced by Bill Hauter

Requires DFPR to review medical licenses and controlled substances registrations in tandem, issuing both at the same time to speed prescriber onboarding.

Rule 19(a) / Re-referred to Rules Committee
0
WeVote Research Nonpartisan
Bill Summary · HB 2769

Summary — HB 2769: “Medical License Review”

Note on source materials: The packet provided included text from two different bills both labeled HB 2769 (an Arizona state land transfer and an Illinois health/regulatory bill). This summary addresses the Illinois measure titled in your file as MEDICAL LICENSE REVIEW (amendment to the Medical Practice Act of 1987).

Purpose

To streamline and coordinate the licensing process for physicians in Illinois by requiring the Department of Financial and Professional Regulation (DFPR) to review and issue an applicant’s medical license and controlled substances registration concurrently, reducing administrative delay before a newly licensed physician may prescribe controlled substances.

Key provisions

  • Adds Section 9.4 to the Medical Practice Act of 1987 (codified as 225 ILCS 60/9.4 new).
  • Requires DFPR to:
    • Review an application for a license to practice medicine concurrently with the applicant’s application for a controlled substances registration under Section 302 of the Illinois Controlled Substances Act.
    • Issue the medical license and the controlled substances registration concurrently (i.e., in tandem rather than sequentially).
  • Effective date: upon becoming law (immediate effectiveness as stated in the bill).

Who is affected

  • Primary: Applicants seeking Illinois medical licensure who also require a controlled substances registration (e.g., physicians who will prescribe controlled drugs).
  • Administrative: DFPR — workload and coordination between licensure and controlled substances registration units.
  • Secondary: Employers (hospitals, clinics, pharmacies) and patients — may experience faster onboarding of newly licensed prescribers.

Procedural status (as provided)

  • Introduced: February 2025 (introduced in House).
  • Committee referrals and readings recorded; companion measures noted (SB 1657, HB 313, HB 1556).
  • Records in the packet indicate the bill progressed through readings and was transmitted to and signed by the Governor (signed 2025-04-01). The bill’s text states it takes effect upon becoming law.

Potential impacts and considerations

  • Operational benefit: Shorter time between licensure approval and ability to prescribe controlled substances, reducing delays in patient care and clinician onboarding.
  • Administrative effects: DFPR will need internal coordination/process changes to ensure truly concurrent review and issuance; may require IT/process updates.
  • Public-safety/regulatory considerations: Concurrent issuance accelerates prescribers’ access to controlled-substance authority — ongoing enforcement, monitoring and background checks remain important safeguards.

Legal citation

  • Amendment: Medical Practice Act of 1987 — new Section 9.4 (225 ILCS 60/9.4 new).

If you want, I can: (1) extract exact statutory language from the enacted version, (2) compare this bill to its companions (SB 1657, HB 313, HB 1556), or (3) draft suggested implementation steps for DFPR.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.